Newdelhi:12/4/21:The Expert panel of the Central drug regulator, DCGA has recommended emergency use authorisation to the Russian Vaccine, Sputnik-V. After necessary approval from the DCGA, Sputnik-V will be the third vaccine to get emergency use authorisation from the drug regulator after Covishield and Covaxin. The clinical trial of the vaccine in India is being done by Dr. Reddy’s Lab. The Hyderabad-based, multinational Indian pharma company, Dr. Reddy’s Lab has also inked an agreement with the Russian Direct Investment Fund, RDIF for the supply of the Russian vaccine in India.
The Subject Expert Committee of the Indian drug regulator in its last meeting on 1st April had asked Dr. Reddy to submit data on how the shot activates the body’s immune response against the coronavirus. RDIF has claimed effectiveness of 91.6 percent for the Sputnik V vaccine. Dr. Reddy had applied for emergency use of Sputnik-V in February this year.